The escalating conflict in the Middle East Medicine Supply has begun to disrupt one of the most sensitive global supply chains: the transport of critical medicines. Pharmaceutical companies and logistics providers warn that the ongoing war involving the United States, Israel, and Iran is increasingly interfering with air cargo routes used to deliver life-saving drugs to Gulf countries. These disruptions have raised urgent concerns among healthcare providers about the continuity of treatments, particularly for patients dependent on complex therapies such as cancer medicines. The Gulf region including the United Arab Emirates, Saudi Arabia, Qatar, and Kuwait relies heavily on imported pharmaceutical products delivered through international cargo hubs. Key aviation gateways such as Dubai, Abu Dhabi and Doha play a central role in distributing temperature-sensitive medicines across the region. However, ongoing missile strikes, airspace restrictions and aviation disruptions have complicated these routes, forcing pharmaceutical companies to reroute shipments through alternative corridors. Although healthcare systems in the Gulf have so far avoided immediate shortages, industry analysts warn that prolonged disruptions could trigger supply gaps within weeks. Medicines such as monoclonal antibodies, advanced cancer therapies and certain biologic drugs require strict refrigeration and rapid delivery, meaning delays of even a few days can threaten the integrity of shipments and the stability of treatment schedules. Strategic Air Routes Under Pressure A central factor behind the emerging supply crisis is the disruption of major global air cargo corridors that pass through the Middle East Medicine Supply. Airports in Dubai, Doha and Abu Dhabi function as …